Ubs Asset Management Americas Inc Allovir, Inc. Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.94 - $7.05 $93,247 - $166,852	23,667 New	23,667 $93,000
Q3 2022 Nov 14, 2022	SELL	$4.13 - $8.79 $65,815 - $140,077	-15,936 Reduced 52.46%	14,442 $113,000
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $42,210 - $84,779	3,262 Added 12.03%	30,378 $393,000
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $233,507 - $344,825	13,760 Added 103.02%	27,116 $679,000
Q2 2021 Aug 16, 2021	BUY	$19.44 - $25.06 $259,640 - $334,701	13,356 New	13,356 $263,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.